250,000 Shares in Denali Therapeutics Inc. $DNLI Bought by Boxer Capital Management LLC

Boxer Capital Management LLC purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 250,000 shares of the company’s stock, valued at approximately $3,630,000. Denali Therapeutics makes up approximately 1.2% of Boxer Capital Management LLC’s portfolio, making the stock its 21st largest position. Boxer Capital Management LLC owned 0.17% of Denali Therapeutics at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Denali Therapeutics in the 2nd quarter valued at about $55,224,000. UBS Group AG increased its holdings in Denali Therapeutics by 111.7% in the third quarter. UBS Group AG now owns 2,012,353 shares of the company’s stock valued at $29,219,000 after buying an additional 1,061,589 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Denali Therapeutics by 58.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock valued at $22,732,000 after buying an additional 614,555 shares in the last quarter. Holocene Advisors LP bought a new position in Denali Therapeutics during the 2nd quarter worth approximately $5,640,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Denali Therapeutics in the 2nd quarter worth approximately $5,548,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $20.57 on Friday. Denali Therapeutics Inc. has a 12-month low of $10.57 and a 12-month high of $23.77. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of -6.93 and a beta of 1.02. The business has a 50 day simple moving average of $19.87 and a 200 day simple moving average of $17.50.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same period in the prior year, the company posted ($0.67) EPS. On average, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Wolfe Research initiated coverage on Denali Therapeutics in a research report on Monday, February 23rd. They set a “peer perform” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, January 21st. BTIG Research lifted their price target on shares of Denali Therapeutics from $32.00 to $36.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Morgan Stanley reaffirmed an “overweight” rating and set a $40.00 price objective on shares of Denali Therapeutics in a research report on Thursday, January 8th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $40.00 target price on shares of Denali Therapeutics in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.20.

Insider Transactions at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 35,198 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the completion of the transaction, the chief executive officer owned 296,833 shares in the company, valued at $4,897,744.50. This represents a 10.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Alexander O. Schuth sold 17,218 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $284,097.00. Following the transaction, the insider directly owned 282,828 shares in the company, valued at approximately $4,666,662. The trade was a 5.74% decrease in their position. The SEC filing for this sale provides additional information. 12.50% of the stock is owned by insiders.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.